Merck Aims to Apply RNAi Expertise to microRNA Mimic Development

Merck is primarily focused on miRNA mimics since the molecules are "somewhat analogous" to siRNAs, which enables the company to piggyback on the know-how of its RNAi subsidiary Sirna Therapeutics.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.